PT3478693T - Derivados de ácido borónico e suas utilizações terapêuticas - Google Patents

Derivados de ácido borónico e suas utilizações terapêuticas

Info

Publication number
PT3478693T
PT3478693T PT17821161T PT17821161T PT3478693T PT 3478693 T PT3478693 T PT 3478693T PT 17821161 T PT17821161 T PT 17821161T PT 17821161 T PT17821161 T PT 17821161T PT 3478693 T PT3478693 T PT 3478693T
Authority
PT
Portugal
Prior art keywords
acid derivatives
boronic acid
therapeutic uses
therapeutic
boronic
Prior art date
Application number
PT17821161T
Other languages
English (en)
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of PT3478693T publication Critical patent/PT3478693T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/05Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT17821161T 2016-06-30 2017-06-28 Derivados de ácido borónico e suas utilizações terapêuticas PT3478693T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357165P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
PT3478693T true PT3478693T (pt) 2021-10-25

Family

ID=60785544

Family Applications (1)

Application Number Title Priority Date Filing Date
PT17821161T PT3478693T (pt) 2016-06-30 2017-06-28 Derivados de ácido borónico e suas utilizações terapêuticas

Country Status (23)

Country Link
US (4) US10294249B2 (pt)
EP (1) EP3478693B1 (pt)
JP (1) JP7060245B2 (pt)
KR (1) KR102403296B1 (pt)
CN (1) CN109415386B (pt)
AU (1) AU2017290060B2 (pt)
BR (1) BR112018077015B1 (pt)
CA (1) CA3026582A1 (pt)
CL (1) CL2018003681A1 (pt)
CO (1) CO2018013978A2 (pt)
DK (1) DK3478693T3 (pt)
ES (1) ES2894251T3 (pt)
IL (1) IL263450B (pt)
MX (1) MX2018015892A (pt)
MY (1) MY196909A (pt)
PH (1) PH12018502747A1 (pt)
PL (1) PL3478693T3 (pt)
PT (1) PT3478693T (pt)
SA (1) SA518400742B1 (pt)
SG (1) SG11201811549UA (pt)
UA (1) UA124464C2 (pt)
WO (1) WO2018005662A1 (pt)
ZA (1) ZA201808327B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691468T3 (es) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivados de éster del ácido borónico cíclicos y usos terapéuticos de los mismos
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
EP3592362A4 (en) 2017-03-06 2020-09-02 Venatorx Pharmaceuticals, Inc. SOLID FORMS AND COMBINATION COMPOSITIONS WITH A BETA LACTAMASE INHIBITOR AND USES THEREOF
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
JP7377545B2 (ja) * 2017-10-11 2023-11-10 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体およびその合成
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2020257306A1 (en) 2019-06-19 2020-12-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
TW202123945A (zh) * 2019-09-13 2021-07-01 日商鹽野義製藥股份有限公司 具有抗菌作用的醫藥組成物
AU2020371404A1 (en) * 2019-10-25 2022-05-19 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
TW202200157A (zh) * 2020-03-18 2022-01-01 美商Qpex生物製藥股份有限公司 化合物ⅱ'的晶形、化合物及其用途、製造其的方法以及醫藥組合物
KR20230020419A (ko) * 2020-05-05 2023-02-10 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 합성, 다형체 형태, 그리고 이들의 치료적 용도
CN116615431A (zh) 2020-08-20 2023-08-18 辉诺生物医药科技(杭州)有限公司 硼酸类化合物
BR112023020348A2 (pt) * 2021-04-05 2023-11-21 Qpex Biopharma Inc Regimes de dosagem de ceftibuteno
CN116917298A (zh) 2021-04-13 2023-10-20 上海拓界生物医药科技有限公司 作为β-内酰胺酶抑制剂的硼酸衍生物
CN113150022B (zh) * 2021-04-23 2022-12-06 四川大学 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途
WO2023066292A1 (zh) * 2021-10-19 2023-04-27 上海济煜医药科技有限公司 三环类硼酸衍生物及其制备方法和应用
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
CN114716465B (zh) * 2022-05-06 2024-05-24 上海中医药大学 一种双环硼酸酯类化合物的制备方法及其应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) * 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
AU8140898A (en) 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
KR20020030126A (ko) 1999-09-25 2002-04-22 피터 기딩스 5―ht1b 길항제로서의 피페라진 유도체
WO2001030149A1 (en) 1999-10-28 2001-05-03 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
CN1189469C (zh) 2000-09-14 2005-02-16 潘斯瑞克有限公司 作为抗菌剂的3-(杂芳基乙酰氨基)-2-氧化-氮杂环丁烷-1-磺酸衍生物
WO2002054931A2 (en) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
JP3714948B2 (ja) 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
EP2325226A1 (en) 2002-10-30 2011-05-25 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
WO2004058679A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク GSK−3阻害剤としての置換2H−[1,2,4]トリアゾロ[4,3−a]ピラジン
KR100918322B1 (ko) * 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
NZ598441A (en) 2005-02-16 2013-07-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
PL1965798T3 (pl) 2005-12-07 2012-02-29 Basilea Pharmaceutica Ag Użyteczne antybiotyki monobaktamowe
SI2719388T1 (sl) 2006-02-16 2019-06-28 Anacor Pharmaceuticals, Inc. Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
NZ579375A (en) 2007-03-23 2012-02-24 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
CA2694068C (en) * 2007-07-23 2016-08-30 The Board Of Trustees Of The University Of Illinois System for controlling the reactivity of boronic acids
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
GB0719366D0 (en) 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CN101861324A (zh) 2007-11-13 2010-10-13 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
CA2712783C (en) 2008-01-18 2013-03-19 Timothy A. Blizzard Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110124634A1 (en) 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
WO2010104818A1 (en) * 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
AU2010281439A1 (en) 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
ES2691468T3 (es) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivados de éster del ácido borónico cíclicos y usos terapéuticos de los mismos
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102320960A (zh) 2011-08-02 2012-01-18 安徽东健化工科技有限公司 一种6-氟水杨酸的制备方法
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
EP2802593A1 (en) 2012-01-09 2014-11-19 The University of Tromsoe Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2654692C2 (ru) 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX361717B (es) 2013-03-15 2018-12-14 Intrexon Corp Diacilhidrazinas que contienen boro.
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
DK3140310T3 (da) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc Syntese af boronatsalte og brug deraf
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406A4 (en) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20170252351A1 (en) 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
SG11201811345TA (en) 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
LT3512851T (lt) 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体およびその合成
TW201925201A (zh) 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
WO2020112542A1 (en) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2020257306A1 (en) 2019-06-19 2020-12-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20220054364A (ko) 2019-08-29 2022-05-02 아릭사 파마슈티컬스 인코포레이티드 박테리아 감염을 치료하기 위해 경구 투여되는 베타-락탐 항생제 및 아비박탐 유도체의 조합

Also Published As

Publication number Publication date
JP7060245B2 (ja) 2022-04-26
SG11201811549UA (en) 2019-01-30
AU2017290060A1 (en) 2018-12-20
CL2018003681A1 (es) 2019-04-26
CN109415386B (zh) 2022-04-19
UA124464C2 (uk) 2021-09-22
MY196909A (en) 2023-05-09
RU2018143900A3 (pt) 2020-09-29
PH12018502747A1 (en) 2019-12-11
EP3478693B1 (en) 2021-07-21
BR112018077015B1 (pt) 2022-05-03
AU2017290060B2 (en) 2021-07-22
CO2018013978A2 (es) 2019-02-08
US20180002351A1 (en) 2018-01-04
BR112018077015A2 (pt) 2019-04-02
DK3478693T3 (da) 2021-09-20
RU2018143900A (ru) 2020-07-30
US10570159B2 (en) 2020-02-25
IL263450A (en) 2019-01-31
EP3478693A4 (en) 2020-02-19
JP2019527196A (ja) 2019-09-26
US11180512B2 (en) 2021-11-23
WO2018005662A1 (en) 2018-01-04
MX2018015892A (es) 2019-06-20
US11999759B2 (en) 2024-06-04
CN109415386A (zh) 2019-03-01
KR20190025953A (ko) 2019-03-12
US20200181177A1 (en) 2020-06-11
US20220056055A1 (en) 2022-02-24
CA3026582A1 (en) 2018-01-04
IL263450B (en) 2022-01-01
KR102403296B1 (ko) 2022-05-27
ES2894251T3 (es) 2022-02-14
US20190233443A1 (en) 2019-08-01
ZA201808327B (en) 2022-04-28
EP3478693A1 (en) 2019-05-08
US10294249B2 (en) 2019-05-21
SA518400742B1 (ar) 2023-02-28
PL3478693T3 (pl) 2021-12-13

Similar Documents

Publication Publication Date Title
ZA201808327B (en) Boronic acid derivatives and therapeutic uses thereof
ZA201608682B (en) Boronic acid derivatives and therapeutic uses thereof
EP3145936A4 (en) Boronic acid derivatives and therapeutic uses thereof
HK1247614A1 (zh) 治療化合物及其用途
HK1243073A1 (zh) 治療性化合物及其用途
EP2941246A4 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
HK1223628A1 (zh) β- 新的 -酮- β-烷基膽烷酸衍生物在製備奧貝膽酸以及其在醫藥領域的用途
EP2941247A4 (en) Boronic acid derivatives and therapeutic uses thereof
IL273551A (en) Boronic acid derivatives and their synthesis
HK1248697A1 (zh) 治療化合物及其用途
ZA201802256B (en) Compounds and therapeutic uses thereof
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
HK1231376A1 (zh) 局部製劑及其應用
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
IL265269B (en) New compounds and their medicinal uses
GB201418809D0 (en) Therapeutic agents and uses thereof
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
PL3250181T3 (pl) Formulacja farmaceutyczna na bazie minoksydylu do stosowania miejscowego i jej zestaw
EP3204003A4 (en) Selenosugars and therapeutic uses thereof
HK1251558A1 (zh) 新的酰亞胺衍生物及其作為藥物的用途
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
GB201615560D0 (en) Novel compounds and therapeutic uses thereof
AU2014901186A0 (en) Therapeutic Agents and Uses Thereof
AU2015901219A0 (en) Therapeutic compounds and uses thereof
GB201417777D0 (en) Novel compounds and therapeutic uses thereof